See every little thing you should make funding decisions proper in the dashboard. A shortcut to view the full list of positions in your portfolio? Click the portfolio icon to get details about shares you own with out leaving the research page.
Business Description Enzolytics, Inc. (the “Company” or “ENZC”) is a drug improvement firm dedicated to the commercialization of its proprietary proteins for the remedy of debilitating infectious ailments. The Company is dedicated to creating medicine for the better health of mankind. ENZC’s flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment , which research have proven is effective in the remedy of HIV. IPF is the lively drug substance of ITV-1 and is a purified extract of porcine pepsin. IPF is a platform technology that can be used to facilitate a broad vary of applications. It is free from main neurological, gastrointestinal and hematological unwanted effects seen in the anti-retrovirals in use right now.
Insufficient data to determine if ENZC’s dividend payments have been rising. Unable to gauge ENZC’s dividend yield in opposition to the top 25% of dividend payers, as the company has not reported any current payouts. Unable to evaluate ENZC’s dividend yield in opposition to the bottom 25% of dividend payers, as the company has not reported any latest payouts. This is kind of a uncommon state of affairs as 97% of corporations coated by SimplyWall St do have past monetary knowledge. Such forward-looking statements are based on present expectations. They contain inherent dangers and uncertainties, including factors that would delay, divert or change any of the statements made, and cause precise outcomes and outcomes to differ materially from current expectations.
To see all change delays and phrases of use please see disclaimer. Fundamental company information provided by Zacks Investment Research. View our full suite of economic calendars and market data tables, all for free.
Enzolytics, Inc. is a drug growth biotechnology firm. The Company is engaged in the commercialization of its proteins for the remedy of debilitating infectious illnesses. The Company is targeted in creating monoclonal antibody remedy and treating infectious ailments. It has anti-HIV therapeutics and a technique for producing totally human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has developed a cell line that produces absolutely human monoclonal antibodies that concentrate on and neutralizes the HIV virus.
Sign up to receive the most recent news and ratings for ENZC and its competitors with MarketBeat’s FREE every day publication. Barchart Futures is a twice weekly e-newsletter that features a choice of the most recent and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox. Explore sturdy dividend paying firms within the Pharmaceuticals & Biotech trade. Unable to calculate sustainability of dividends as ENZC has not reported any payouts.
Patent Application for producing totally human monoclonal antibodies, is at present employed to produce monoclonal antibody therapeutics for quite a few infectious illnesses, including the CoronaVirus (SARS-CoV-2) and HTLV-1. In this section, we normally attempt to help traders decide whether Enzolytics is buying and which of the following is not one of the current key technology trends that raises ethical issues? selling at a beautiful value based on the money move it’s anticipated to produce sooner or later. Intraday Data supplied by FACTSET and subject to phrases of use. Historical and present end-of-day data supplied by FACTSET.
This website uses cookies.